Literature DB >> 4840426

Usefulness of an erythromycin-resistant strain of Mycoplasma pneumoniae for the fermentation-inhibition test.

Y Niitu, S Hasegawa, H Kubota.   

Abstract

The fermentation-inhibition (FI) test for Mycoplasma pneumoniae was performed with two strains of M. pneumoniae, one susceptible to erythromycin and one highly resistant to erythromycin with cross-resistance to other macrolide antibiotics. Serum titers in children with M. pneumoniae pneumonia who received no antibiotic were similar with the two strains. Children with atypical pneumonia with a transient rise in the FI titer with the susceptible strain proved to have received erythromycin at the time of the rise. They showed no rise in the FI titer done with the erythromycin-resistant strain. Oral administration of erythromycin regularly elevated the serum FI titer when the test was done with the susceptible strain. Use of the resistant strain in the test eliminated this false elevation. Tetracycline and chloramphenicol did not elevate the titer, even with the susceptible strain. Use of the strain of M. pneumoniae resistant to erythromycin provides a true FI antibody serum titer, avoiding the influence of antibiotics.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4840426      PMCID: PMC428930          DOI: 10.1128/AAC.5.2.111

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Mycoplasma pneumoniae and adenovirus respiratory illnesses in military and university personnel, 1959-1966.

Authors:  W J Mogabgab
Journal:  Am Rev Respir Dis       Date:  1968-03

2.  Possible influence of antibiotic therapy on usefulness of metabolic inhibition test for diagnosis of Mycoplasma pneumoniae infections.

Authors:  T F Smith; E C Herrmann
Journal:  Appl Microbiol       Date:  1971-01

3.  Antimetabolic antibodies to Mycoplasma pneumoniae measured by tetrazolium reduction inhibition.

Authors:  L B Senterfit; K E Jensen
Journal:  Proc Soc Exp Biol Med       Date:  1966-07
  3 in total
  1 in total

1.  In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae.

Authors:  Y Nitu; S Hasegawa; H Kubota
Journal:  Antimicrob Agents Chemother       Date:  1974-05       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.